Unfortunately, single agent mTOR inhibitors such as rapamycin (sirolimus, CCL-779) that specifically complexes with FK506-binding protein 12 (FKBP12), thereby interacting allosterically and inhibiting mTOR (Figure 1), has produced minimal clinical activity and improvement in neuroimaging of recurrent glioblastoma patients [47, 48]. Here, FKBP1A is linked to glioblastoma.